Go to the profile of BerGen Bio

BerGen Bio

 
Go to the profile of HAOJUN LIAN
HAOJUN LIAN

BD, Innovent Biologics

Go to the profile of Najoua Borkadi
Najoua Borkadi

Business Development Associate Director, University of Michigan

Go to the profile of Carmen Ramirez
Carmen Ramirez

Sales Account Executive, Springer Nature

Oxford Vacmedix was established in 2012 as a spinout from Oxford University. Its aim is to develop therapeutic and diagnostic agents for the treatment and monitoring of cancer based on the invention of Dr Shisong Jiang - Recombinant Overlapping Peptides (ROP). These agents are an exciting new way to deliver immunotherapy which is now a major focus in the treatment of cancer, making it easier to deliver, more effective and much more economical. The company currently has two candidates in development. One targeting HPV for cervical cancer and one against Survivin/IAP for a range of solid tumours.
Founded in London (United Kingdom) in 2016, MicroQuin was born out of a collaborative and inclusive approach to research. MicroQuin is a biotechnology, R&D based company currently focusing on developing therapeutics to address a range of oncological disease. MicroQuin is progressing lead compounds into clinical trials, which offer a potential cure to Breast Cancer and other diseases.
Go to the profile of Albany A. Cordova Martins
Albany A. Cordova Martins

Business Development Executive, Nature Publishing Group, Springer Nature